参考文献

［1］Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes［J］. NEngl J Med, 2016, 375(4): 323-334.

［2］Patorno E, Pawar A, Franklin JM, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care［J］. Circulation, 2019, 139(25): 2822-2830.(https://www.daowen.com)

［3］Bailey CJ, Marx N. Cardiovascular protection in type 2 diabetes: insights from recent outcome trials［J］. Diabetes ObesMetab, 2019, 21(1): 3-14.

（盛雪汉）